Fresh off its approval from the US Food and Drug Administration, Axsome Therapeutics’ migraine drug Symbravo (meloxicam and rizatriptan) stands to potentially strengthen its position in a crowded marketplace, with data showing it can treat patients who have not responded well to the CGRP inhibitors that currently dominate that market.
Axsome said 24 February that the open-label Phase III EMERGE trial of Symbravo among patients experiencing inadequate response to oral...
Welcome to Scrip
Create an account to read this article
Already a subscriber?